Skip to Content
MilliporeSigma
All Photos(1)

Documents

04273

Sigma-Aldrich

Sodium phosphate dibasic dodecahydrate

meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)

Synonym(s):

sec-Sodium phosphate, Disodium hydrogen phosphate dodecahydrate, Disodium phosphate, di-Sodium hydrogen phosphate dodecahydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
Na2HPO4 · 12H2O
CAS Number:
10039-32-4
Molecular Weight:
358.14
EC Number:
231-448-7
MDL number:
MFCD00149181
UNSPSC Code:
12161700
PubChem Substance ID:
329747907
NACRES:
NA.25

agency

meets analytical specifications of BP
meets analytical specifications of Ph. Eur.

assay

98.5-102.5% (T)

form

crystals

quality

meets analytical specification of Ph. Eur., BP, E339

impurities

reducing matter, complies
 residual solvents, complies
≤0.001% heavy metals (as Pb)
≤1.0% NaH2PO4
57-61% water (Karl Fischer)

loss

57-61% loss on drying

pH

8.4-9.6 (20 °C, 1%)

anion traces

chloride (Cl-): ≤10 mg/kg
fluoride (F-): ≤10 mg/kg
sulfate (SO42-): ≤100 mg/kg

cation traces

As: ≤1 mg/kg
Cd: ≤1 mg/kg
Cu: ≤20 mg/kg
Fe: ≤10 mg/kg
Hg: ≤1 mg/kg
K: ≤50 mg/kg
Pb: ≤4 mg/kg
Zn: ≤10 mg/kg

suitability

complies for appearance of solution

SMILES string

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChI key

DGLRDKLJZLEJCY-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application


  • Study of the Influence of Alkalizing Components on Matrix Pellets Prepared by Extrusion/Spheronization: This publication examines the effects of sodium phosphate dibasic dodecahydrate as an alkalizing agent in matrix pellets, showcasing its application in improving the physicochemical properties of pellets, which are crucial for controlled drug delivery systems (Hamedelniel EI, Bajdik J, Kasa P Jr, Pintye-Hodi K, 2012).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matthew H Crouthamel et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(11), 2625-2632 (2013-08-24)
Elevated serum phosphate has emerged as a major risk factor for vascular calcification. The sodium-dependent phosphate cotransporter, PiT-1, was previously shown to be required for phosphate-induced osteogenic differentiation and calcification of cultured human vascular smooth muscle cells (VSMCs), but its
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service